{"id":18110,"date":"2017-12-21T09:58:39","date_gmt":"2017-12-21T09:58:39","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=18110"},"modified":"2018-11-06T06:48:07","modified_gmt":"2018-11-06T06:48:07","slug":"biochemical-changes-related-with-temporomandibular-joint-disorders-and-inflammatory-arthritis","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol10no4\/biochemical-changes-related-with-temporomandibular-joint-disorders-and-inflammatory-arthritis\/","title":{"rendered":"Biochemical Changes Related with Temporomandibular Joint Disorders and Inflammatory Arthritis"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Temporomandibular joint and muscle disorders are a group of situations that cause pain and dysfunction in the jaw joint and the muscles that control jaw movement.1<\/sup><\/p>\n

Patients with TMD most commonly existent with imperfect mandibular motion, TMJ sounds, and pain.2<\/sup>\u00a0The pain is often restricted to the jaw, muscles of mastication, and TMJ sounds. Common related symptoms as tinnitus, ear pain and stuffiness, neck pain, dizziness, and headache. Sometimes, the case is acute and symptoms are mild and self-limiting. In other patients, a chronic TMD develops, with persistent pain and physical, psychological, behavioral, and psychosocial symptoms parallel to those of patients with chronic pain syndromes in other parts of the body,3<\/sup>\u00a0e.g. chronic headache, chronic regional pain syndrome, arthritis, low back pain, and fibromyalgia, totally needing a diagnostic and dealing method.4<\/sup><\/p>\n

The occurrence of TMJ involvement in inflammatory arthritis is frequently undervalued, and practice in treatment among rheumatologists is incomplete. Three situations have an affinity toward the TMJ: psoriatic arthritis (PA), ankylosing spondylitis (AS), and rheumatoid arthritis (RA). The prevalence is the highest in RA, followed by PA.5<\/sup><\/p>\n

Patients with RA are at risk of TMJ involvement, and 67-71% patients will have at least one symptom. Typical and clinical outcomes include stiffness, joint pain, sounds, and limitation of movement.6<\/sup>\u00a0Patients with RA tend to have more recurrent and severe signs, symptoms, and radiographic alterations when compared to PA \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0and AS patients.7<\/sup><\/p>\n

Disease-modifying anti-rheumatic drugs can diminish joint injury by suppressing inflammation in all of the inflammatory arthritis, and the target of the rheumatologist should be to complete remission if possible.8<\/sup><\/p>\n

In fact, RA is an autoimmune disease with a high multifaceted physiopathology. The major initiating incident could be the triggering of antigen-dependent T cells leading to an essentially Th1 type immune response. The consequent effects are various, counting the activation and the proliferation of endothelial and synovial cells, recruitment and activation of pro-inflammatory cells, secretion of cytokines like interleukin-1 (IL-1), proteases by macrophages and fibroblast-like synovial cells, and production of autoantibodies.9<\/sup><\/p>\n

Thus, association between vitamin D and RA has been broadly deliberated, and the data persist debated. Certain studies demonstrate that RA patients have lesser concentrations of vitamin D.10,11<\/sup><\/p>\n

Calcium (Ca+2<\/sup>) is the main content in bones and joints and intracellular, free Ca+2<\/sup> has an imperative role in muscle contraction and Ca+2<\/sup> deficiency, as a medical situation, also has numerous of the same symptoms and characteristics.12<\/sup>\u00a0The concentration of Ca+2<\/sup> in serum is usually reserved in a very limited range so as to prevent the disorder of some physiological roles, such as muscle contraction.13<\/sup>\u00a0Bone is a mineral reservoir for Ca+2<\/sup> and phosphorus. Over 99% of total Ca+2<\/sup> in human body is kept in bone and teeth. Calcium plays significant roles in the formation process of new bone and conservation of existing bone by cooperating with other factors such as phosphorus, vitamin D and Ca+2<\/sup>-binding proteins.14<\/sup><\/p>\n

The objective of this study was to determine vitamin D, Ca+2<\/sup>, total ALP activity, and IL-1 in sera of TMD patients suffer from RA.<\/p>\n

Materials and Methods<\/strong><\/p>\n

The present study was performed in the Medical City Hospital during the period\u00a0 from January 2017 until the end of July 2017. It was conducted on 45 TMD patients 15 males (33.33%) and 30 females (66.66%). The ages ranging from (47-70) years with mean age (58.50) years. While remaining 45 apparently healthy subjects were selected as controls. The differential diagnosis of TMD included: periodontal disease and caries.<\/p>\n

Laboratory Tests<\/em><\/strong><\/p>\n

Routine investigations including ESR were recorded.<\/p>\n

Serum vitamin D, total ALP activity, Ca+2<\/sup> were measured using a chemical analyzer in the medical laboratories. Cytokines levels were determined in sera via a sandwich immunoassay kit provided by Human IL-1.<\/p>\n

Radiographic Examination<\/em><\/strong><\/p>\n

Rheumatologists evaluated the joints most commonly affected in the RA. The TMJ images were performed at the Oral Radiology Department\/ College of Dentistry-University of Baghdad.<\/p>\n

Statistical Analysis<\/em><\/strong><\/p>\n

Descriptive statistics were presented as mean (\u00b1SD). Correlation coefficient was used to assess the relationships between vitamin D and other variables studied.<\/p>\n

Results<\/strong><\/em><\/p>\n

Signs and symptoms in TMD patients illustrate in table (1). Pain in and around the TMJ, headaches, and limited movement represent the higher ratios in TMD patients (greater than 80 %).<\/p>\n

Table 1: Signs and symptoms in TMD patients<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Signs and Symptoms<\/strong><\/td>\nTMD Patients (n,%)<\/strong><\/td>\n<\/tr>\n
Headaches<\/td>\n40 (88.90 %)<\/td>\n<\/tr>\n
Pain in the temple area<\/td>\n30 (66.70 %)<\/td>\n<\/tr>\n
Pain in and around the TMJ<\/td>\n45 (100 %)<\/td>\n<\/tr>\n
Back pain and stiffness in the neck<\/td>\n28 (62.22 %)<\/td>\n<\/tr>\n
Limited movement and opening of the jaw<\/td>\n36 (80 %)<\/td>\n<\/tr>\n
Earaches<\/td>\n21 (46.70 %)<\/td>\n<\/tr>\n
Dizziness<\/td>\n18 (40 %)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Anthropometric characteristics of the studied groups are in table (2).<\/p>\n

Table 2: Anthropometric characteristics of the studied groups<\/strong><\/p>\n\n\n\n\n\n\n\n
Parameter<\/strong><\/td>\nTMD with RA\u00a0<\/strong>(n= 45)<\/strong><\/td>\nControl\u00a0<\/strong>(n= 45)<\/strong><\/td>\nP value<\/strong><\/td>\n<\/tr>\n
Age (years)<\/td>\n\u00a012.60\u00b1 50.58<\/td>\n\u00a08.50\u00b143.02<\/td>\n0.001<\/td>\n<\/tr>\n
Male\/ Female<\/td>\n15\/30<\/td>\n22\/23<\/td>\n–<\/td>\n<\/tr>\n
SBP (mmHg)<\/td>\n138.40 \u00b1 2.65<\/td>\n123.18 \u00b1 1.12<\/td>\n0.001<\/td>\n<\/tr>\n
DBP (mmHg)<\/td>\n83.50 \u00b1 2.26<\/td>\n74.60 \u00b11.94<\/td>\n0.01<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

There was a significant increases in age, systolic- and diastolic blood pressure (SBP, DBP) in TMD patients as compared to the controls.<\/p>\n

Table (3) shows the laboratory characteristics of the studied groups. There was a significant decrease in vitamin D in TMD patients as paralleled to the controls, (P= 0.001). While a significant increase in serum total ALP activity and IL-1 in TMD patients as paralleled to the controls, (P= 0.01).<\/p>\n

Table 3: Laboratory characteristics of the studied groups<\/strong><\/p>\n\n\n\n\n\n\n\n
Parameter<\/strong><\/td>\nTMD with RA\u00a0<\/strong>(n= 45)<\/strong><\/td>\nControl\u00a0<\/strong>(n= 45)<\/strong>\u00a0\u00a0<\/strong><\/td>\nP value<\/strong><\/td>\n<\/tr>\n
Vitamin D (IU\/ml)<\/td>\n30.40 \u00b1 13.50<\/td>\n55.24 \u00b1 32.28<\/td>\n0.001<\/td>\n<\/tr>\n
Ca+2 <\/sup>(mg\/dl)<\/td>\n6.20 \u00b1 0.65<\/td>\n11.5 \u00b1 0.55<\/td>\n0.52<\/td>\n<\/tr>\n
Total ALP (U\/L)<\/td>\n133.42 \u00b1 26.50<\/td>\n124.0 \u00b1 18.90<\/td>\n0.01<\/td>\n<\/tr>\n
IL-1 (\u03c1g\/ml)<\/td>\n12.55 \u00b1 8.22<\/td>\n4.0 \u00b1 1.35<\/td>\n0.01<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

There was a reduction in serum Ca+2<\/sup> levels in TMD patients as paralleled to the controls, but it was not significant.<\/p>\n

Correlations coefficient between serum vitamin D and other parameters in TMD\u00a0 group in table (4) showed that there was a significant negative correlation between serum vitamin D activity with total ALP activity and IL-1 in TMD patients, (P= 0.001).<\/p>\n

Table 4: Correlations between serum vitamin D and other parameters in TMD group<\/strong><\/p>\n\n\n\n\n\n\n
\u00a0<\/em>Vitamin D (IU\/ml)<\/strong><\/td>\nCorrelation coefficient (r)<\/strong><\/td>\n<\/tr>\n
Ca+2 <\/sup>(mg\/dl)<\/td>\n0.23<\/td>\n<\/tr>\n
Total ALP (U\/L)<\/td>\n-0.95**<\/td>\n<\/tr>\n
IL-1 (\u03c1g\/ml)<\/td>\n-0.90**<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

** P = 0.001<\/em><\/p>\n

Discussion<\/strong><\/p>\n

Temporomandibular disorders are a collective cause of craniofacial pain, it is imperative for the health care supplier to find a comprehensive history, complete physical investigation, and find suitable investigative methods to eliminate other potentially serious disorders.15<\/sup><\/p>\n

The most collective symptom recounted by patients with TMD is unilateral facial pain. Severe pain usually generated by movements of the mandible and may be existing regular or\u00a0 occasionally. 16<\/sup><\/p>\n

Vitamin D is required to control Ca+2<\/sup> absorption and homeostasis. Low levels of vitamin D have been concerned in a numeral of chronic diseases including RA.17<\/sup>\u00a0Moreover, it is complicated in IL-2 inhibition, antibody production, and in lymphocyte proliferation, and, thus, is reflected a regulator of the immune system crucial in the development and function of both T-regulatory cells and dendritic cells.18<\/sup><\/p>\n

This is the first study investigating the associations between vitamin D and TMD. However, consistent evidence recommends that higher intakes of Ca+2<\/sup>, dairy-foods and vitamin D are inversely connected with caries and periodontitis.19<\/sup>\u00a0Dietary Ca+2 <\/sup>absorption is critical for Ca+2<\/sup> availability for bone mineralization and vitamin D status is a significant parameter influencing intestinal Ca+2 <\/sup>absorption.20<\/sup>\u00a0Current data, therefore, suggests that well vitamin D intakes facilitate beneficial effects of higher Ca+2 <\/sup>intakes, probably by improvement of Ca+2<\/sup> absorption.<\/p>\n

Calcium and vitamin D is required to improve and conserve healthy bones and teeth. Sufficient Ca+2<\/sup> intake is essential for all peoples and particularly for RA patients which are vulnerable to steroid-induced and disease related osteoporosis. In RA, vertebral bone density has been found to be 5-15% less than aged matched controls.21<\/sup>\u00a0Furthermore, corticosteroids, used in the management of RA, impair intestinal Ca+2<\/sup> absorption.22<\/sup><\/p>\n

Experimental evidence suggests that vitamin D effects the process by which immune cells acquire signaling molecules that permit them to transfer to normal extra lymphoid tissue sites, in addition to sites of inflammation 23<\/sup>. Additionally, it is celebrated that biologically active form of vitamin D 1,25-(OH)2<\/sub>D3<\/sub> inhibits IFN-\u03b3 secretion and negatively controls IL12 production by down regulating NF-\u03baB.24<\/sup><\/p>\n

In this study, patients ALP activity is higher relative to control, which is in agreement with the study of Kumar et al.,25<\/sup><\/p>\n

According to the present data, ALP showed a strong negative correlation\u00a0 with vitamin D.<\/p>\n

The role of ALP is implicated in osteoid formation and mineralization and expression of its isoform is in osteoblasts, leucocytes, breast, liver, kidney, and brain. The bone construction markers are measured in serum and about 1\/2 of ALP in serum comes from bone. Increased activity may be due to inflammatory cytokines as interleukin-1 (IL-1) which has been associated with the acute phase reactants levels.26<\/sup>\u00a0The role of T-cells is well recognized in the pathogenesis of RA. Increased ALP activity may be due to its leakage from injured or killed cells. Alkaline phosphatase has been implicated as marker in RA patients. It can offer diagnostic evidence by measurements of isoform of ALP activity derived from bone or liver.27<\/sup><\/p>\n

Interleukin-1 is one of the most predominant and first cytokines produced as a response to excessive loading of the TMJ.28<\/sup>\u00a0Ahmed et al., investigated the association of IL-1 and TMD in RA patients and found a relationship between IL-1 and RA.29<\/sup><\/p>\n

Conclusions<\/strong><\/p>\n

This study demonstrated that serum vitamin D levels were significantly lower in TMD patients with RA. Vitamin D insufficiency is predominant in patients with RA compared to healthy subjects. Calcium and vitamin D levels correlate inversely with RA activity and related with vulnerability to RA and RA activity in TMD patients. Additionally, IL-1 provide a more reliable and complete profile of inflammatory contributors to TMD.<\/p>\n

Acknowledgement<\/strong><\/p>\n

I would like to thank the College of Dentistry\/ University of Baghdad for helping me to complete this research.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

No conflict of interest.<\/p>\n

Funding Source<\/strong><\/p>\n

The author.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Basso D., Correa E., Silva A. M.\u00a0 Efeito da reeduca\u00e7\u00e3o postural global no alinhamento corporal e nas condicoes clinicas de indiv\u00edduos com disfuncao temporomandibular associada a desvios posturais. Fisioterapia e Pesquisa.<\/em> 2010;17(1):63-68.
    \nCrossRef<\/a><\/li>\n
  2. Wright E. F., Sarah L., North S. L. Management and Treatment of Temporomandibular Disorders: A Clinical perspective. The journal of manual & manipulative therapy<\/em>. 2009;17(4):247-254.
    \n    CrossRef<\/a><\/li>\n
  3. Wolfe F., Ross K., Anderson J., Russell I. J., Hebert L. The Prevalence and Characteristics of Fibromyalgia in the General Population. Arthritis Rheum.<\/em> 1995;38(1):19\u201328.
    \n    CrossRef<\/a><\/li>\n
  4. Wilson L., Dworkin S. F., Whitney C and LeResche L. Somatization and Pain Dispersion in Chronic Temporomandibular Disorder pain. Pain.<\/em> 1994;57:55-61.
    \n    CrossRef<\/a><\/li>\n
  5. Aliko A., Ciancaglini R., Alushi A., Tafaj A., Ruci D. Temporomandibular Joint\u00a0 Involvement in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Int J Oral Maxillofac Surg.<\/em> 2011;40:704-709.
    \n    CrossRef<\/a><\/li>\n
  6. Bessa-Nogueira R. V., Vasconcelos B. C., Duarte A. P., Goes P. S., Bezerra T. P. Targeted Assessment of the Temporomandibular Joint in Patients with Rheumatoid Arthritis. J Oral Maxillofac Surg<\/em>. 2008;66:1804-1811.
    \n    CrossRef<\/a><\/li>\n
  7. Kononen M., Wenneberg B., Kallenberg A. Craniomandibular Disorders in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. A clinical Study. Acta Odontol Scand.<\/em> 1992;50:281-287.
    \n    CrossRef<\/a><\/li>\n
  8. Callhoff J., Sieper J., Weiss A., Zink A., Listing J. Efficacy of TNF\u03b1 Blockers in Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: A meta-analysis. Ann Rheum Dis.<\/em> 2015;74:1241-1248.
    \n    CrossRef<\/a><\/li>\n
  9. Marques C. D., Dantas A. T., Fragoso T. S and Duarte A. L. The Importance of Vitamin D Levels in Autoimmune Diseases. Bras J Rheumatol.<\/em> 2010;50(1):67\u201380.<\/li>\n
  10. Antico A., Tampoia M., Tozzoli R and Bizzaro N. Can Supplementation with Vitamin D Reduce the Risk or Modify the Course of Autoimmune Diseases? A systematic review of the literature. Autoimmunity Reviews<\/em>. 2012;12(2):127\u2013136.
    \n    CrossRef<\/a><\/li>\n
  11. Varenna M., Manara M., Cantatore F. et al. Determinants and Effects of Vitamin D Supplementation on Serum 25-Hydroxy-vitamin Levels in Patients with Rheumatoid Arthritis. Clinical and Experimental Rheumatology<\/em>. 2012;30(5):714\u2013719.<\/li>\n
  12. Gelbard A. Fibromyalgia Possibly the Result of Calcium Deficiency by Amos Gelbard. Human Anat J.<\/em> 2017;1(1):000103.<\/li>\n
  13. Brini M., Ottolini D., Cali T., Carafoli E. Calcium in Health and Disease.Met. Ions Life Sci<\/em>. 2013;13:81\u2013137.
    \n    CrossRef<\/a><\/li>\n
  14. Beto J. A. The Role of Calcium in Human Aging. Clin. Nutr. Res.<\/em> 20154(1):1-8.<\/li>\n
  15. Okeson J. P. General Considerations in the Treatment of Temporoman-dibular Disorders. Management of Temporomandibular Disorders and Occlusion. St. Louis, Missouri: Mosby. 2003;367-411.<\/li>\n
  16. Leeuw R. D., Klasser G. D.\u00a0 American Academy of Orofacial Pain. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. 5th ed. Chicago, Ill.: Quintessence Publ. 2013<\/li>\n
  17. O\u2019Connor A.\u00a0 An Overview of the Role of Diet in the Treatment of Rheumatoid Arthritis. Nutrition Bulletin.<\/em> 2013;39:74-88.
    \n    CrossRef<\/a><\/li>\n
  18. Maruotti N., Cantatore F.\u00a0 P. Vitamin D and the Immune System. J Rheumatol.<\/em> 2010;37:491-495.
    \n    CrossRef<\/a><\/li>\n
  19. Grant W. B., Boucher B. J. Are Hill\u2019s Criteria for Causality Satisfied for Vitamin D and Periodontal Disease? Dermatoendocrinol.<\/em> 2010;2:30\u201336.
    \n    CrossRef<\/a><\/li>\n
  20. Adegboye A. R., Christensen L. B., Holm-Pedersen P., Avlund K., Boucher L., and Heitmann B. L. Intakes of Calcium, Vitamin D, and Dairy Servings and Dental Plaque in Older Danish adults. Nutrition Journal.<\/em> 2013;12(61):1-5.
    \n    CrossRef<\/a><\/li>\n
  21. Adachi J. D., Bell M. J., Bensen W. G., Bianchi F., Cividino A. et al. Fluoride Therapy in Prevention of Rheumatoid Arthritis Induced Bone Loss. J Rheumatol<\/em>. 1997;24:2308-2313.<\/li>\n
  22. Reid I. R., Veale A. G., France J. T. Glucocorticoid Osteoporosis. J Asthma.<\/em> 1994;31:7-18.
    \n    CrossRef<\/a><\/li>\n
  23. Weiss S. T. Bacterial Components Plus Vitamin D: the Ultimate Solution to the Asthma (Autoimmune Disease) Epidemic? J Allergy Clin Immunol<\/em>. 20111;127: 1128-1130.
    \n    CrossRef<\/a><\/li>\n
  24. Boonstra A., Barrat F. J., Crain C., Heath V. L., Savelkoul H. F., et al. 1-Alpha, 25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4(+) T Cells to Enhance the Development of Th2 Cells. J Immunol<\/em>. 2011;167:4974-4980.
    \n    CrossRef<\/a><\/li>\n
  25. Kumar V., Prakash J., Gupta V., Khan M. Y. Antioxidant Enzymes in Rheumatoid Arthritis. J Arthritis<\/em>. 2016;5:206:1-5.
    \n    CrossRef<\/a><\/li>\n
  26. Thompson P. W., Houghton B. J., Clifford C., Jones D. D., Whitaker K. B. et al. The Source and Significance of Raised Serum Enzymes in Rheumatoid Arthritis. Q J Med.<\/em> 1990;76:869-879.<\/li>\n
  27. Vaithialingam A., Lakshmi T. M., Suryaprakash G., Edukondalu A. D., Reddy EP. Alkaline Phosphatase Levels in Rheumatoid Arthritis and Osteoporosis in Clinical Practice. Journal of Current Trends in Clinical Medicine and laboratory biochemistry.<\/em> 2013;1:20-23.<\/li>\n
  28. Kim Y. K., Kim S. G., Kim B. S., et al. Analysis of the Cytokines Profiles of the Synovial Fluid in a Normal Temporomandibular joints: Preliminary Study. Craniomaxillofac. Surg.<\/em> 2012;40:337-341.
    \n    CrossRef<\/a><\/li>\n
  29. Ahmed N., Petersson A., Catrina A. I., et al. Tumor Necrosis Factor Mediates Temporomandibular Joints Bone Tissue Resorption in Rheumatoid Arthritis. Acta Odontol Scand.<\/em> 2015;73(3):232-240.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Temporomandibular joint and muscle disorders are a group of […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[],"class_list":["post-18110","post","type-post","status-publish","format-standard","hentry","category-vol10no4"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=18110"}],"version-history":[{"count":13,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18110\/revisions"}],"predecessor-version":[{"id":23909,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18110\/revisions\/23909"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=18110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=18110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=18110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}